Glenmark Pharmaceuticals has cut price of antiviral drug Favipiravir --sold under the brand name FabiFlu for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet. The company had launched the drug in June at a price of Rs 103 per tablet.
The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country.
Glenmark Pharmaceuticals is a global researchled pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.45 |
| Dr. Reddys Lab | 1234.80 |
| Cipla | 1241.25 |
| Zydus Lifesciences | 948.10 |
| Lupin | 2332.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: